Breakingviews - Biotech upstarts will be Big Pharma's China tonic
HONG KONG (Reuters Breakingviews) - A dose of Chinese biotech could be beneficial for Big Pharma. AstraZeneca is launching a $1 billion healthcare fund in the Peopleâ€™s Republic. A wealthier, older society promises huge growth for drugmakers, but the burden for the state means Beijing is already pressing global heavyweights to lower prices. Investing in local discoveries and exporting them could be a smart remedy.
